- Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by AstraZeneca as a limited distribution specialty pharmacy provider for ETCAMAH® (camizestrant).
- Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Takeda to be part of a limited network of a specialty pharmacy providers for MIMRYLO™ (rusfertide). This newly FDA-approved, first-in-class therapy is indicated for the treatment of erythrocytosis in adults with polycythemia vera (PV) and is administered via subcutaneous injection.
- Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Cycle Pharmaceuticals as a limited distribution specialty pharmacy provider for CAVHANZA™ (nilotinib) Orally Disintegrating Tablets.
- Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Revolution Medicines as a specialty pharmacy provider for RASONQUE™ (daraxonrasib) within its distribution network.
- - Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, and rare disease therapies, has been selected by Rigel Pharmaceuticals as the hub and a limited distribution specialty pharmacy provider for VEPPANU™ (vepdegestrant).
- Effective July 13, Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) will be supported by Biologics by McKesson as a limited distribution specialty pharmacy partner.